Why the study?
Is 'aspirin resistance' clinically relevant in high-risk obstetrics?
Is 'aspirin resistance' clinically relevant in high-risk obstetrics?
This review highlights the emerging concept of aspirin resistance in high-risk obstetric populations and its potential clinical relevance for pre-eclampsia prevention.
Answers are grounded in this paper and cite their sources.
Aspirin non-responsiveness may limit pre-eclampsia prevention; leaves open need for resistance testing and optimized regimens in trials.
UNLABELLED: Antiplatelet agents are pivotal for prevention of coronary artery disease and cerebrovascular disease worldwide. Individual patient data meta-analysis indicates that low-dose aspirin causes a 10% risk reduction in pre-eclampsia for women at high individual risk. However, in the last 15 years it has emerged that a significant proportion of aspirin-treated individuals exhibit suboptimal platelet response, determined biochemically and clinically, termed 'aspirin non-responsiveness', 'aspirin resistance' and 'aspirin treatment failure'. More recently, investigation of aspirin responsiveness has begun in pregnant women. This review explores the history and clinical relevance of 'aspirin resistance' applied to high-risk obstetric populations. TWEETABLE ABSTRACT: Is 'aspirin resistance' clinically relevant in high-risk obstetrics?
No takes yet. Share an insight, caveat, or question.
Navaratnam et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: